drugset

drugset / Trial / NCT00632502

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

NCT00632502 ↗

Phase 2 Completed 37 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupTriple-blindTreatment

Summary

4-Week Safety Study in Subjects with Neutrophilic Asthma

Timeline

Start: 2008-05-01
Primary completion: 2009-02-01
Completion: 2009-02-01

Publications

Results Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P; Study Investigators. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012 Jul;42(7):1097-103. doi: 10.1111/j.1365-2222.2012.04014.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NAVARIXIN ANHYDROUS	Small molecule	30 mg	Oral
Background	Salbutamol	Unknown	—	—

Indications